Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)

NCT06974344 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Small-for-Size Syndrome

Interventions

DRUG: Octreotide (drug)
PROCEDURE: Splenic Artery Ligation (SAL)

Sponsor

King Faisal Specialist Hospital & Research Center